Key Highlights

● Fortrea delivered a profit in its most recent quarter.

● The contract research organization cut $558 million from its Backlog after a contract review.

● The company reported on Oct. 29.

● The company split from Labcorp.

Fortrea (NASDAQ:FTRE)'s most recent quarter delivered something its shareholders had rarely seen since the company split from Labcorp: a profit. Yet the contract research organization also cut $558 million from its backlog after a contract review, and that tension continues to hang over the stock two weeks after the Oct. 29 report.

What the third quarter showed

According to the company's Oct. 29 release, Fortrea posted third-quarter Revenue of $691.5 million, down from $701.3 million a year earlier, a decline of about 1.4%. GAAP Net Income was $0.6 million, or 1 cent a share, compared with a net loss of $15.9 million in the year-earlier period. Adjusted EBITDA rose to $58.0 million from $50.7 million, and adjusted diluted Earnings were 28 cents a share, up from 12 cents.

New Business held up. The book-to-bill ratio, which compares new awards with revenue recognized, was 1.12 times for the quarter, matching the trailing 12-month figure, which suggests Demand has been fairly steady over the past year. A reading above 1 means the company is booking more work than it is burning through. CEO Anshul Thakral said in the release that sustained bookings momentum is building a foundation for growth.

The company also raised the midpoints of its full-year guidance and narrowed the ranges. Fortrea now expects 2026 revenue of $2.665 billion to $2.690 billion and adjusted EBITDA of $210 million to $218 million.

The backlog reset

The less comfortable number was the backlog. Fortrea reported adjusted backlog of $7.316 billion at Sept. 30 after a $558 million reduction stemming from a review of contracts. The company said the adjustment did not affect historical results, current 2026 guidance or near-term revenue estimates. Still, backlog is the pipeline from which future revenue flows, and a write-down of that size invites questions about the quality of past bookings and about revenue beyond the near term.

Why it matters, and the risks

Fortrea, headquartered in Durham, North Carolina, runs Clinical Trials and related services for drug and medical-device developers. It was spun off from Labcorp in 2023 and has since dealt with separation costs, Margin pressure and a reshuffled Leadership team. Its business depends on biopharma research budgets, which are sensitive to biotech funding conditions and pharmaceutical cost cutting.

Higher rates are a headwind for biotech funding, and the 10-year Treasury Yield was near 5% on Thursday morning, with futures markets pricing a likely Federal Reserve hike in December. Key company risks include contract cancellations, competition from larger contract research organizations, and Debt carried since the spin-off.

Looking ahead, investors will watch for any further backlog adjustments, trends in book-to-bill and whether revenue returns to growth. Fortrea's fourth-quarter report, which would include 2027 guidance, would typically come in late February or early March. In the meantime, biotech funding activity and peer contract research organization commentary will offer clues on demand.